新冠特效藥板塊走高,翰宇藥業(300199.SZ)大漲15%
格隆匯3月15日丨新冠特效藥概念股繼續走高,翰宇藥業(300199.SZ)直線拉昇漲約15%,廣生堂漲超9%,舒泰神漲超6%,迦南科技、君實生物等跟漲。

翰宇藥業昨日在互動平台表示,自2021年11月15日以來,多肽新冠鼻噴劑藥物項目工作團隊全力以赴,目前僅四個月不到時間已經完成了對奧密克戎(Omicron)及德爾塔(Delta)兩主要流行株的活毒研究,抑制效果明顯;動物體內藥效研究和非臨牀藥理毒理研究均推進中。針對當前的研究進展與研究方案已與國家藥審中心進行了溝通,並得到了針對性的回覆。
此外,翰宇藥業昨日晚間發公吿稱,公司擬與國研中心、市三院合作開發家用快速型新型冠狀病毒抗原檢測試劑盒,國研中心及市三院擬將該試劑盒(乙方編號P301-F7和P301-H5兩條抗體,以及後續與該項目相關的專利)的全球獨佔實施許可權許可給翰宇藥業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.